CACTIS promotes translational research, featuring preclinical and clinical investigations, especially molecular imaging technologies, such as molecular breast imaging (MBI). Other interests include Quantitative PET/CT, Diffusion-weighted MRI, and comparative assessments of new biomarkers. These studies, in addition to the evaluation of new detector systems, will be performed in cooperation with the Arizona Institute for Advanced Imaging (AI2) and routinely published to assorted health media networks for distribution through handheld mobile devices.
Evaluating new and novel diagnostic and therapeutic technologies will be carried out in the context of rural and urban community clinical care with unique and focused cultural (epigenomic) emphasis. This will be augmented by sponsorship and participation in educational programs that advocate adoption and training for health care providers in the use of these techniques and treatment. CACTIS will hold ongoing Continuing Medical Education programs and will archive all courses for long-term availability through a vast media net using handheld mobile devices to promote Best Practices in patient management.
Collaborations are underway with the Optical Sciences Department and the Cancer Healthcare Disparities Institute (CHDI) at the University of Arizona (Tucson, AZ), Banner Orthopaedic Residency Program (Phoenix, AZ), and Cedars-Sinai Medical Center (Los Angeles, CA) regarding new methods for the noninvasive imaging of benign and malignant diseases. The programs are directed at enabling comparative effectiveness analysis of the outcomes of standard therapies, as well as early and later stage clinical trials.
Molecular Imaging: the Future of Diagnostic Medicine
